
About Abionic
Abionic is a Healthcare company based in Epalinges (Switzerland) founded in 2010 by Iwan MΓ€rki and Nicolas Durand. Point-of-care diagnostic tools for allergy profiles are provided. Abionic has raised $28.94 million across 4 funding rounds from investors including Zurcher Kantonalbank, Pierangelo Bottinelli and Philippe Glatz. Its chief executive, as recorded, is Patrick Pestalozzi. Abionic offers products and services including abioSCOPE and PSP Assay. Its focus areas include Life Sciences, Infectious Diseases, In Vitro Diagnostic Tests and Bacterial.
Company details
Abionic was founded in 2010 and is based in Epalinges, Switzerland. Diagnostic tools for allergies are developed by the company within the healthcare sector. Operations focus on point-of-care solutions, including the abioSCOPE device for measuring IgE concentrations from blood samples, the abioGUIDE application for report viewing on mobile devices, and screening capsules that assess respiratory allergies using minimal blood volume.
- Headquarters Epalinges, Switzerland
- Founders Iwan Märki, Nicolas Durand
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website abionic.com
- Social LinkedIn X Facebook
- Total Equity Funding$28.94M (USD)
in 4 rounds
- Latest Funding Round$21.13M (USD), Series C
Mar 2018
- InvestorsZurcher Kantonalbank
& 14 more
Products & Services of Abionic
Abionic offers a comprehensive portfolio of products and services, including abioSCOPE and PSP Assay.
Rapid tool for sepsis detection from blood samples in minutes.
Test to detect sepsis risk using Pancreatic Stone Protein.
Funding Insights of Abionic
Abionic has successfully raised a total of $28.94M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $21.13 million completed in March 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $28.94M
- Total Rounds 4
- Last Round Series C β $21.13M
- First Round $127,765
(Oct 2010)
- Investors Count 15
All 4 funding rounds of Abionic with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2018 | $21.13M | Series C | β | Pierangelo Bottinelli | |
| Oct 2014 | $3.99M | Series B | β | β | |
| Apr 2012 | $3.7M | Series A | β | MedHoldings | |
| Oct 2010 | $127,765 | Seed | β | Venture Kick | β |
15 investors in total: 9 institutional and 6 angel.
Investors in Abionic
Abionic has secured backing from 15 investors, including angel, institutional, and venture fund investors. Prominent investors backing the company include Zurcher Kantonalbank, Pierangelo Bottinelli and Philippe Glatz.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on science and tech-driven startups | verve.vc | Berlin, Germany | ||
Investment in early-stage medical device and life science companies with network support. | blueocean-ventures.com | |||
Business Angels Switzerland is focused on investing in innovative startups. | businessangels.ch | Worb, Switzerland | ||
| fongitseedinvest.com | ||||
| medholdings.com | ||||
Early-stage tech startups in Switzerland and the US are funded. | polytechventures.ch | Ecublens, Switzerland | ||
University backed startup accelerator | venturekick.ch | Schlieren, Switzerland | ||
Commercial banking services are provided across Switzerland by Zurcher Kantonalbank. | 1870 | zkb.ch | Zurich, Switzerland | |
Investment management services are provided by Drexel Morgan & Co. | 1979 | drexelmorgan.com | Radnor, United States | |
PB Pierangelo Bottinelli | unknown_8dc5c7b1b2944c47b |
Investor details for Abionic
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Abionic
11 people are tracked at Abionic (8 in leadership, 3 in board & advisors).
| Name | Role | Group |
|---|---|---|
Iwan Märki | Co-Founder & CTO | Leadership |
Nicolas Durand | Co-Founder | Leadership |
Patrick Pestalozzi | CEO | Leadership |
Stéphane Broillet | Head of Engineering | Leadership |
François Ventura | Chief Medical Officer | Leadership |
Jelena Nesic | Head of QC | Leadership |
Jean-Marc Reck | Head Of Human Resources And Administration | Leadership |
Guillaume Haquette | Chief Biology Officer | Leadership |
Martine Reindle | President of the Board of Directors | Board & advisors |
Nader Donzel | Director | Board & advisors |
Eric Cornut | Director | Board & advisors |
Complete people profiles for Abionic
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Abionic
3 dated milestones of Abionic across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Abionic is founded.
- Funding First funding round of $128K.
- Funding Latest funding round, Series C, of $21.1M.
Web traffic of Abionic
Websites that share an audience with Abionic (abionic.com).
Websites whose visitors overlap most with Abionic. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biocartis.com | 100% | 10.5K | #2,065,137 | View details | |
| acimmune.com | 99% | 11.3K | #1,671,085 | View details | |
| hayesinc.com | 63% | View details | |||
| acplus.com | 63% | 7.1K | #3,043,935 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Abionic
Complete news archive for Abionic
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Abionic
Abionic was founded in 2010.
Abionic is headquartered in Epalinges, Switzerland. It is registered at Epalinges, Vaud, Switzerland.
Patrick Pestalozzi is the CEO of Abionic, as recorded in our data.
Abionic is a funded company, having raised a total of $28.94M across 4 funding rounds to date. The company's 1st funding round was a Seed of $127.77K, raised on Oct 2010.
Abionic was founded in 2010 and is based in Epalinges, Switzerland. Diagnostic tools for allergies are developed by the company within the healthcare sector. Operations focus on point-of-care solutions, including the abioSCOPE device for measuring IgE concentrations from blood samples, the abioGUIDE application for report viewing on mobile devices, and screening capsules that assess respiratory allergies using minimal blood volume.
Abionic offers abioSCOPE and PSP Assay.
Abionic has 15 investors. Key investors include Zurcher Kantonalbank, Pierangelo Bottinelli, Philippe Glatz, Arkady Volozh, and Peter Brabeck-Letmathe.
